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Abstract  
Introduction 
A new prothrombin time reagent (Revohem™ PT) based on recombinant human tissue factor 
produced by the silkworm-baculovirus expression system was tested. The aim of this study was to 
compare the performance of the new PT reagent with two widely used routine PT reagents. 
Methods 
All testing was performed on a Sysmex CS-5100 coagulometer. Revohem™ PT was tested for 
imprecision and stability using normal and abnormal lyophilised commercial control plasmas. 
Comparability was assessed with two widely used reagents; one containing recombinant human 
tissue factor (Reagent A) and the other a human placental thromboplastin (Reagent B) using a wide 
range of normal and abnormal plasmas and analyser specific ISI values.  
Results 
Excellent between-day imprecision was obtained for Revohem™ PT (CV < 1.0%) and acceptable open 
vial on-board stability over 7-days. There was good agreement between methods in samples from 
patients with liver disease and patients receiving warfarin and no significant differences between 
methods with increasing INR values. Both recombinant reagents suffered less interference from 
lupus anticoagulant than the placental thromboplastin. Revohem™ PT had similar sensitivity to 
reagents A and B for FII, V, VII and X deficiency; and demonstrated dose responsiveness to 
Dabigatran, Apixaban and Rivaroxaban with steeper response curves than the comparison reagents 
Conclusions 
Revohem™ PT showed comparable or improved performance relative to two widely used reagents 
and is suitable for use in warfarin control, detection of inherited factor II, V, VII and X deficiency and 
assessment of liver disease coagulopathy. 
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Introduction 
The prothrombin time (PT) is widely used for monitoring vitamin K antagonist anticoagulant therapy. 
It is also used and as a screening test for single or combined deficiencies of the extrinsic coagulation 
pathway due to inherited defects or acquired defects due to liver disease . Currently there is 
considerable interest in the sensitivity of PT reagents to direct oral anticoagulants (DOAC) because 
DOAC might interfere in screening for coagulopathies in patients bleeding where the anticoagulation 
status of the patient is unknown, and in determining whether a patient is still anticoagulated (e.g. 
prior to surgery). Recombinant thromboplastins, using recombinant tissue factor (generated in 
bacteria) and synthetic phospholipids are sensitive PT reagent which overcome much of the lot to lot 
availability associated with thromboplastins prepared from traditional biological sources . Insect 
systems are widely used to produce proteins from higher eukaryotes because they have a similar 
pattern of glycosylation, phosphorylation, and protein processing. We report on the performance of 
a novel prothrombin time reagent (Revohem™ PT, Sysmex Corporation, Kobe, Japan) which utilises 
human recombinant tissue factor produced by the silkworm-baculovirus expression system and 
synthetic phospholipids. Revohem™ PT was tested for imprecision, stability and comparability to two 
widely used PT reagents (Reagent A and Reagent B) in a wide range of sample types.  
Materials and methods 
Blood samples taken into 0.105M sodium citrate (Vacutainer, Becton Dickinson, Oxford, UK) from 
100 patients receiving warfarin anticoagulation, 26 with known lupus anticoagulant and 45 with liver 
disease were obtained from residual, anonymised samples collected after all routine testing had 
been completed, in compliance with local ethical committee rules and the Human Tissue Act. All 
testing was performed on a Sysmex CS-5100 coagulometer (Sysmex Corporation). Revohem™ PT is a 
lyophilised reagent containing recombinant human tissue factor, synthetic phospholipids, calcium 
ions, a heparin neutralizing compound, amino acids, HEPES and preservatives. The comparison 
reagents were a recombinant human thromboplastin (Reagent A) and a lyophilized human placental 
thromboplastin (Reagent B). ISI assignment and INR calibration were performed using certified 
reference plasmas (AK calibrant, Technoclone, Vienna, Austria) on 5 different days as previously 
described . Imprecision and reagent stability were assessed by testing normal and abnormal control 
plasmas (Dade® Ci-Trol® levels 1 and 2, Siemens Healthcare, Marburg, Germany).  
Normal reference ranges were derived using citrated plasma collected locally from 90 apparently 
normal healthy volunteers and 50 commercially sourced normal plasmas (CRYOcheck™ Normal 
Donor Set, Precision BioLogic Inc. Dartmouth, Canada). Informed consent was obtained from normal 
donors (approved by the UCL Research Ethics Committee. Project ID Number: 7029/001).  
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Sensitivity to factor deficiencies was assessed by testing immunodepleted plasmas deficient in factor 
II, factor V, factor VII and factor X (CRYOcheck, Precision BioLogic or Hyphen Biomed immune-
depleted deficient plasma) supplemented with normal reference plasma (CRYOcheck, Precision 
BioLogic or locally prepared pooled normal plasma) to achieve concentrations of approximately 10%, 
20%, 30%, 40%, 50%, 60%, 70% and 80% of normal. In addition, plasma from eleven patients with 
congenital factor V deficiencies (6 FV, 2 FVII and 3 FX) were also tested. The factor II, V, VII and X 
levels were verified by one-stage PT-based assays using multiple dilution analysis and fibrinogen 
levels by Clauss assay, using reagents from Siemens Healthcare. Heparin sensitivity was assessed by 
spiking normal plasma with unfractionated and low molecular weight heparin at 0.1, 0.2, 0.4, 1.0 and 
1.5 IU/mL. Sensitivity to direct oral anticoagulants was assessed by testing plasma from patients 
receiving Rivaroxaban, Apixaban and Dabigatran where available, in addition to normal plasma 
samples spiked with drug, plasma controls and calibrators (Hyphen Biomed, Neuville-sur-Oise, 
France) to achieve a range of concentrations.  
Statistical analysis was performed on Excel (Microsoft, WA, USA) and Minitab 17 (State College, PA, 
USA). Parametric statistics were used unless otherwise stated. Correlation plots were made using 
Pearson’s coefficient of correlation. A probability value of p<0.05 was considered statistically 
significant. Normal reference ranges were defined by the mean  2 standard deviations of log 
transformed data.  
 
Results 
Locally assigned ISI values were 1.00 for Revohem™ PT, 1.02 for Reagent A and 1.07 for Reagent B. 
Revohem™ PT demonstrated < 1% imprecision with both normal and abnormal control plasmas over 
5 days (Table 1). To assess reagent stability, freshly reconstituted normal and abnormal controls 
were tested at day 0, day 4, day 7 and day 8 using an open 8 mL vial of Revohem™ PT which was 
stored on-board the analyser. After 7 days, the PT measurements for the normal and abnormal 
control plasmas had decreased by 4.1% and 5.4% relative to day 0. Normal reference ranges and 
geometric mean PTs were established in 140 normal plasmas (Table 2).  
Comparability was assessed in 100 plasma samples from patients receiving warfarin using the local 
INR calibration. Revohem™ PT demonstrated good correlation with Reagent A (Figure 1a) with no 
significant differences between methods with increasing INR values for samples within the 
therapeutic range, although Reagent A appeared to give higher INR values above the therapeutic 
range (Figure 1b). A difference of more than 0.5 INR units was observed in 10 samples (6 higher by 
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Reagent A and 4 higher by Revohem™ PT), but 7 of these samples were from patients with an INR 
>4.5 using Reagent A. Revohem™ PT also showed good correlation with Reagent B (Figure 1c), again 
with no significant differences between methods and no discernible trend with increasing INR values 
for samples within the therapeutic range (Figure 1d).The two comparison reagents demonstrated 
good correlation (Figure 1e) although Reagent A appeared to give slightly higher INRs above the 
therapeutic range (Figure 1f). 
 
Figure 1a 
Figure 1b 
Figure 1c  
Figure 1d.  
Figure 1e 
Figure 1f 
Sensitivity to lupus anticoagulant was assessed in 26 patients with lupus anticoagulant tested 
according to the most recent ISTH criteria . All had positive dilute Russell viper venom ratios and/or 
Taipan/Ecarin ratios. As all 26 patients were also receiving warfarin, equal volume mixes of these 
plasmas with pooled normal plasma were also tested. Excellent correlation was obtained between 
Reagent A and Revohem™ PT (Figure 2a), with an average difference of -0.14. Only two samples 
showed a difference of more than 0.5 INR units. Reagent B and Revohem™ PT also showed excellent 
correlation (Figure 2c) but Reagent B gave significantly higher INR values (difference 0.34, p <0.0001) 
with 14 samples showing a difference of more than 0.5 INR units. The two comparison reagents 
demonstrated excellent correlation (Figure 2c) but Reagent B again gave significantly higher INR 
values (difference 0.32, p <0.0001). 
The effect of haemostatic abnormalities secondary to liver disease was studied in 45 patients with a 
median MELD score  of 15 (range 9 – 32). Good correlation was observed between reagents (Figures 
3d-e).A small but statistically significant difference between Revohem™ PT and Reagent A (Wilcoxon 
signed rank p = 0.008) was observed but this difference was not clinically significant (all <0.5 PT 
ratio).  
Figure 2a  
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Figure 2b 
Figure 2c 
Figure 2d 
Figure 2e 
Figure 2f 
The sensitivity for specific factor deficiencies was determined by plotting the factor level against PT 
(Figures 3a –d) to determine the highest concentration of a given factor to produce prolongation of 
the PT above the upper limit of the normal reference range. Revohem™ PT demonstrated similar 
sensitivity to factors II, V, VII and X as the two comparison reagents (Table 3). All deficient plasmas 
had normal levels of the non-depleted extrinsic factors (0.80 – 1.20 IU/mL for II, V, VII and X) and 
fibrinogen (2.5 -3.0 g/L). Five plasmas from patients deficient in factor V (<0.01, 0.08, 0.19, 0.18 and 
0.33 IU/dL), two plasmas from patients deficient in factor VII (0.12 and 0.24 IU/dL) and three 
plasmas from patients deficient in factor X (0.03, 0.04 and 0.21 IU/dL) all had prolonged PT with all 
three reagents. Both Revohem™ PT and Reagent A were insensitive to unfractionated and low 
molecular weight heparin levels of up to 1.5 IU/mL (i.e. < 5% increase above the PT of untreated 
plasma, whereas Reagent B suffered interference with unfractionated heparin at 1 IU/mL (data not 
shown). Revohem™ PT was more sensitive to Dabigatran, Rivaroxaban and Apixaban than Reagent A 
or Reagent B (figure 3) which demonstrated similar sensitivities to those previously reported .  
Figure 3a  
Figure 3b 
Figure 3c 
Figure 3d  
Figure 3e 
Figure 3f 
Figure 3g 
Discussion 
We report on the performance of the first PT reagent to use human recombinant tissue factor 
generated by the silkworm-baculovirus expression system  Revohem™ PT was compared to two 
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widely used PT reagents. Revohem™ PT demonstrated acceptable levels of imprecision and open vial 
stability. Excellent comparability of INR values was achieved within the therapeutic range in plasma 
from patients receiving warfarin and of PT ratios in plasma from patients with liver disease, and 
there were no significant trends with increasing INR. Since it has been suggested that some PT 
reagents give unreliable INR values in the presence of lupus anticoagulant , 26 plasma samples with 
lupus anticoagulant and equal volume mixes of the same plasmas with pooled normal plasma were 
tested by all three methods. Revohem™ PT suffered less interference from lupus anticoagulant than 
the placental thromboplastin (Reagent B) and had similar sensitivity to reagent A.  
The comparison reagents were less sensitive to reduction in FII than to reductions in FV, FVII and FX 
as previously reported . The sensitivity of Revohem™ PT to FV, FVII and FX was similar to that of the 
comparison reagents. Reagent B was slightly more sensitive to FII than Revohem™ PT or Reagent A. 
The prothrombin time is known to have limited utility for the detection of mild clotting factor 
deficiencies in the extrinsic pathway . It should be emphasised that the prothrombin time is a global 
test, which is influenced by the levels of all clotting factors within a spiked deficient plasma, not just 
the clotting factor that has been adjusted . Although guidance is available on the assessment of 
coagulation factor sensitivity of the APTT no clear information has been provided for PT, but it is 
generally assumed that similar mixing studies may be informative. The factor sensitivity data and ISI 
determination both indicate that Revohem PT is highly sensitive to factors II, V, VII and X . The 
apparent oversensitivity to factors V, VII and X may be explained by the inherent problems with 
error associated with mixing tests, including problems with mixing plasmas from different sources, 
the impact of any buffers and stabilisers that a manufacturer may have added (in both PT reagents 
and plasmas), as well as differences in citrate concentration. In the case of factor V, due to its 
thermal lability, it is also possible that there is some loss of FV activity during the course of the 
experiment, so that actual FV levels were lower than those predicted. It has been suggested that the 
use of well characterised patient samples with a single deficiency of each extrinsic factor (covering 
the range of desired sensitivity; 30-50%) might offer  a better approach than mixing (spiking) 
experiments , but such samples are difficult to obtain in suitable numbers. 
The sensitivity of PT reagents to DOACs is highly variable , so plasma samples from patients receiving 
Rivaroxaban and Dabigatran, standards and controls and normal plasma spiked with Dabigatran, 
Apixaban and Rivaroxaban at a range of concentrations were tested by all three methods. The 
comparison reagents were relatively insensitive to Rivaroxaban and Apixaban as previously reported 
. Revohem™ PT demonstrated dose responsiveness to all three DOACs with steeper response curves 
than the comparison reagents. It has been reported that the use of drug calibrators may over-
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estimate the sensitivity of PT reagents to DOACs  and our data from patients receiving Rivaroxaban 
(Figure 3) support this. Unfortunately, it was not possible to obtain sufficient samples from patients 
receiving Dabigatran or Apixaban to compare with drug spiked plasmas. Although the PT should not 
be used to determine the plasma concentration of DOACs, it is important that laboratories know the 
sensitivity of its PT reagent to them .  
In conclusion, Revohem™ PT showed comparable or improved performance relative to two widely 
used PT reagents and is suitable for use in the control of warfarin, detection of inherited factor II, V, 
VII and X deficiency and assessment of coagulopathy in liver disease. 
Acknowledgements 
The authors would like to thank Dr Will Lester and Chris Watson from the Haematology Department, 
Queen Elizabeth Hospital, Birmingham, UK, and Hannah Cohen, University College London Hospitals, 
UK for providing some of the samples for analysis.The Haemostasis Research Unit have received 
unrestricted educational grants from Sysmex UK. Irfan Patel and Kiyoko Kohama are employees of 
Sysmex UK and Sysmex Japan.   
9 
 
 
References 
1.Quick A.J. (1940) THE THROMBOPLASTIN REAGENT FOR THE DETERMINATION OF PROTHROMBIN. 
Science 92, 113-114. 
2.Baglin T., Keeling D. & Kitchen S. (2012) Effects on routine coagulation screens and assessment of 
anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British 
Committee for Standards in Haematology. Br J Haematol 159, 427-429. 
3.Kitchen S., Gray E., Mackie I., Baglin T. & Makris M. (2014) Measurement of non-coumarin 
anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for 
Standards in Haematology. Br J Haematol 166, 830-841. 
4.Bader R., Mannucci P.M., Tripodi A., Hirsh J., Keller F., Solleder E.M., Hawkins P., Peng M., Pelzer 
H., Teijidor L.M. & et al. (1994) Multicentric evaluation of a new PT reagent based on recombinant 
human tissue factor and synthetic phospholipids. Thromb Haemost 71, 292-299. 
5.Roussi J., Drouet L., Samama M. & Sie P. (1994) French multicentric evaluation of recombinant 
tissue factor (recombiplastin) for determination of prothrombin time. Thromb Haemost 72, 698-704. 
6.Maeda S., Kawai T., Obinata M., Fujiwara H., Horiuchi T., Saeki Y., Sato Y. & Furusawa M. (1985) 
Production of human alpha-interferon in silkworm using a baculovirus vector. Nature 315, 592-594. 
7.van den Besselaar A.M., Barrowcliffe T.W., Houbouyan-Reveillard L.L., Jespersen J., Johnston M., 
Poller L. & Tripodi A. (2004) Guidelines on preparation, certification, and use of certified plasmas for 
ISI calibration and INR determination. J Thromb Haemost 2, 1946-1953. 
8.Pengo V., Tripodi A., Reber G., Rand J.H., Ortel T.L., Galli M. & De Groot P.G. (2009) Update of the 
guidelines for lupus anticoagulant detection. Subcommittee on Lupus 
Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the 
International Society on Thrombosis and Haemostasis. J.Thromb.Haemost. 7, 1737-1740. 
9.Kamath P.S. & Kim W.R. (2007) The model for end-stage liver disease (MELD). Hepatology 45, 797-
805. 
10.Gosselin R., Grant R.P. & Adcock D.M. (2016) Comparison of the effect of the anti-Xa direct oral 
anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol 38, 
505-513. 
11.Van Blerk M., Bailleul E., Chatelain B., Demulder A., Devreese K., Douxfils J., Jochmans K., Mullier 
F., Wijns W., Soumali M.R., Coucke W., Vernelen K. & Van de Walle P. (2015) Influence of dabigatran 
and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost 113, 
154-164. 
12.Della Valle P., Crippa L., Garlando A.M., Pattarini E., Safa O., Vigano D'Angelo S. & D'Angelo A. 
(1999) Interference of lupus anticoagulants in prothrombin time assays: implications for selection of 
adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody 
syndrome. Haematologica 84, 1065-1074. 
13.Massignon D., Moulsma M., Bondon P., Debize G., Abidi H., Buttin T., Bon C., Pillonchery G. & 
Coeur P. (1996) Prothrombin time sensitivity and specificity to mild clotting factor deficiencies of the 
extrinsic pathway: evaluation of eight commercial thromboplastins. Thromb Haemost 75, 590-594. 
14.Lawrie A.S., Kitchen S., Efthymiou M., Mackie I.J. & Machin S.J. (2013) Determination of APTT 
factor sensitivity – the misguiding guideline. International Journal of Laboratory Hematology 35, 652-
657. 
15.CLSI (2009) H47-A2 |One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin 
Time (APTT) Test, 2nd Edition. Clinical and Laboratory Standards Institute 28. 
16.Chandler W.L. (2009) Initial evaluation of hemostasis: reagent and method selection. In: Quality 
in Laboratory Hemostasis and Thrombosis eds S. Kitchen, J. D. Olson & F. E. Preston), pp. 63-71. 
Wiley Blackwell, Oxford  
17.Dumoulin E.N., Fiers L. & Devreese K.M. (2016) Investigation of sensitivity for coagulation factor 
deficiency in APTT and PT: how to perform it? Clin Chem Lab Med 54, e169-172. 
10 
 
18.Testa S., Legnani C., Tripodi A., Paoletti O., Pengo V., Abbate R., Bassi L., Carraro P., Cini M., 
Paniccia R., Poli D. & Palareti G. (2016) Poor comparability of coagulation screening test with specific 
measurement in patients receiving direct oral anticoagulants: results from a 
multicenter/multiplatform study. J Thromb Haemost 14, 2194-2201. 
19.Gosselin R.C., Adcock D., Hawes E.M., Francart S.J., Grant R.P. & Moll S. (2015) Evaluating the use 
of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to 
dabigatran and rivaroxaban. Thromb Haemost 113, 77-84. 
 
  
11 
 
Table 1. 5-day imprecision. Ten measurements were performed on each control plasma each day. 
 Normal plasma Abnormal plasma 
 Revohem™ PT Reagent A  Reagent B  Revohem™ PT Reagent A  Reagent B  
Mean PT (s) 12.4 10.6 11.4 36.1 31.4 39.4 
SD 0.10 0.08 0.15 0.30 0.49 0.49 
% CV 0.81 0.78 1.30 0.83 1.55 1.24 
 
Table 2. Reference ranges from 140 normal subjects 
 Revohem™ PT Reagent A  Reagent B  
Mean PT (s) 11.36 10.86 12.35 
mean – 2SD 9.89 9.48 10.46 
Mean + 2SD  13.06 12.43 14.57 
 
Table 3. Sensitivity to clotting factor deficiencies as determined by the highest factor concentration 
at which the PT was prolonged. 
 Factor II IU/dL Factor V IU/dL Factor VII IU/dL Factor X IU/dL 
Revohem™ PT 24 67 52 59 
Reagent A  28 59 47 52 
Reagent B  48 67 47 58 
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Figure legends 
Figure 1. INR values in 100 plasmas from patients receiving warfarin (circles) and 140 plasmas from 
normal donors (crosses). The regression lines were generated using only plasma from patients 
receiving warfarin with INR values <4.5 (circles), INR values >4.5 (diamonds).a) Reagent A vs 
Revohem™ PT, b) Bland Altman, mean difference for +0.04 INR units; c) Reagent B vs Revohem™ PT. 
d) Bland Altman, mean difference +0.09 INR units (One outlier not shown); e) Reagent A vs Reagent 
B. f)Bland Altman, mean difference -0.09 INR units (One outlier not shown). 
Figure 2. INR values in 26 patients with lupus anticoagulant receiving warfarin (circles) and equal 
volume mixes of the same plasmas (crosses). a) Reagent A vs Revohem™ PT. b) Reagent B vs 
Revohem™. c) Reagent A vs Reagent B. PT ratios in 45 patients with liver disease: e) Reagent A vs 
Revohem™ PT, e) Reagent B vs Revohem™, f) Reagent A vs Reagent B 
 
Figure 3. The effect of single factor deficiency was determined in patient plasma (open symbols) and 
immunodepleted plasmas spiked with pooled normal plasma (closed symbols): a) factor II, b) factor 
V, c) factor VII, d) factor X.  The effect of DOACs on prothrombin time was assessed using patient 
plasma (open symbols) and normal plasma spiked with drug including calibrators and controls 
(closed symbols) e) Dabigatran, f) Apixaban and e) Rivaroxaban 
 
